NTT Enhances Its Managed Campus Networks Portfolio With Palo Alto Networks Prisma® SASE to Address Networking, Security and Business Management Challenges
2.2.2023 13:00:00 EET | Business Wire | Press release
NTT Ltd., a leading global IT infrastructure and services company, today announced the addition of Palo Alto Networks Prisma SASE to its Managed Campus Networks portfolio. The new offering is a comprehensive managed Secure Access Service Edge (SASE) solution that includes SD-WAN, cloud-delivered security, and enhanced automation and reporting. The end-to-end solution is designed to help enterprises meet current digital transformation challenges and enable more flexible ways of working.
By integrating networking and SD-WAN functionality with cloud-delivered security, the solution enables NTT customers to secure user access to applications and sensitive data irrespective of location, without compromising on performance and user experience. The platform’s advanced AIOps and automation capabilities also help improve operational efficiency and security outcomes.
NTT Managed Campus Networks with Prisma SASE provides organizations with immediate and continuous savings, reducing the number of vendors, tools, and technology stacks needed to support the business. The solution is a simple and scalable model with entry points matching customers’ unique journeys and needs. Additionally, as a fully managed solution, enterprises will be able to conserve scarce IT resources and reduce the complexity of managing a global network and security infrastructure.
“We are excited to partner with Palo Alto Networks to provide this end-to-end managed SASE offering that helps customers address the challenges that confront today’s enterprise operational environment,” said Sunil Kishore, Senior EVP Managed Network and Collaboration Services Division at NTT Ltd. “The breadth of our combined technical resources and service capabilities, coupled with NTT’s global presence, will enable us to design, deliver and manage solutions for even the most complex enterprise requirements.”
“NTT’s world-class service, support, and comprehensive set of SLAs provide a strong managed service foundation for our single vendor SASE solution,” added Anand Oswal, Senior Vice President of Products, Network Security at Palo Alto Networks. “NTT Managed Campus Networks with Palo Alto Networks Prisma SASE will play an integral role in enabling organizations to secure their digital transformation journeys through enhanced operational efficiency, agility and effective management of cloud environments, providing a true zero trust solution to safeguard today’s distributed workforce.”
“Conventional security perimeters do not meet the needs of today’s distributed networks,” stated Brian Washburn, Research Director, Service Provider Enterprise & Wholesale at Omdia. “The SASE framework combines SD-WAN with cloud-delivered security to protect sites, clouds, data centers and remote workers. NTT Managed Campus Networks service with Palo Alto Networks Prisma SASE lets enterprises upgrade or address gaps in their network and security, delivered through a flexible cloud model.”
To find out more about NTT’s Managed Campus Networks portfolio click here.
About NTT Ltd.
As part of NTT DATA, a USD 30 billion IT services provider, NTT Ltd. is a leading IT infrastructure and services company serving 65% of the Fortune Global 500 and more than 75% of the Fortune Global 100. We lay the foundation for organizations’ edge-to-cloud networking ecosystem, simplify the complexity of their workloads across multicloud environments, and innovate at the edge of their IT environments where networks, cloud and applications converge. We offer tailored infrastructure and ensure consistent best practices in design and operations across all of our secure, scalable and customizable data centers. On the journey towards a software-defined future, we support organizations with our platform-delivered infrastructure services. We enable a connected future. Visit us at services.global.ntt
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005142/en/
Contact information
Media Enquiries:
Hotwire for NTT Ltd.
Hannah Lock
hannah.lock@hotwireglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom